| Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature N Abdel-Wahab, H Safa, A Abudayyeh, DH Johnson, VA Trinh, ... Journal for immunotherapy of cancer 7, 1-10, 2019 | 262 | 2019 |
| Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature H Safa, DH Johnson, VA Trinh, TE Rodgers, H Lin, ME Suarez-Almazor, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 204 | 2019 |
| Tilsotolimod with Ipilimumab drives tumor responses in anti–PD-1 refractory melanoma C Haymaker, DH Johnson, R Murthy, SE Bentebibel, MI Uemura, ... Cancer discovery 11 (8), 1996-2013, 2021 | 37 | 2021 |
| Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review H Safa, M Tamil, PE Spiess, B Manley, J Pow-Sang, SM Gilbert, F Safa, ... JNCI: Journal of the National Cancer Institute 113 (5), 532-542, 2021 | 28 | 2021 |
| Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive … C Saberian, N Abdel-Wahab, A Abudayyeh, H Rafei, J Joseph, G Rondon, ... Journal for immunotherapy of cancer 9 (2), 2021 | 15 | 2021 |
| The Prognostic Role of Human Papillomavirus and p16 Status in Penile Squamous Cell Carcinoma—A Systematic Review K Parza, A Mustasam, F Ionescu, M Paravathaneni, R Sandstrom, H Safa, ... Cancers 15 (14), 3713, 2023 | 10 | 2023 |
| Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination … J Chadha, JJ Adashek, H Jim, Y Kim, A Semaan, NH Chakiryan, H Safa, ... Clinical genitourinary cancer 20 (2), e158-e165, 2022 | 5 | 2022 |
| Cardiac metastases in melanoma H Safa, IC Glitza Oliva N Engl J Med 380 (9), 858, 2019 | 4 | 2019 |
| 782 Intratumoral sotigalimab with pembrolizumab activates antigen-presenting cells and induces local and distant anti-tumor responses in first-line metastatic melanoma: results … SE Bentebibel, D Johnson, B Pazdrak, D McGrail, S Lecagoonporn, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 3 | 2022 |
| Difficulties in differentiating between checkpoint inhibitor pneumonitis and lung metastasis in a patient with melanoma H Safa, P Bhosale, A Weissferdt, ICG Oliva Immunotherapy 12 (5), 293-298, 2020 | 3 | 2020 |
| Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management H Safa, F Abu Rous, N Belani, H Borghaei, S Gadgeel, B Halmos Targeted Oncology 18 (1), 25-49, 2023 | 2 | 2023 |
| Corrections to: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature N Abdel-Wahab, H Safa, A Abudayyeh, DH Johnson, CM Zobniw, H Lin, ... Journal for immunotherapy of cancer 7 (1), 158, 2019 | 2 | 2019 |
| Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases P Reid, S Sandigursky, J Song, MA Lopez-Olivo, H Safa, S Cytryn, E Efuni, ... OncoImmunology 12 (1), 2261264, 2023 | 1 | 2023 |
| THU0656 IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH CANCER AND RHEUMATOLOGIC DISEASES: A SYSTEMATIC REVIEW OF THE LITERATURE N Abdel-Wahab, H Safa, MA Lopez-Olivo, A Diab, M Suarez-Almazor Annals of the Rheumatic Diseases 78 (Suppl 2), 624-624, 2019 | 1 | 2019 |
| Safety and Effectiveness of Immune Checkpoint Inhibitors Combination versus Single Agent Therapy in Patients with Pre-existing Autoimmune Diseases P Reid, S Sandigursky, MA Lopez-Olivo, J Song, H Safa, S Cytryn, M Buni, ... ARTHRITIS & RHEUMATOLOGY 74, 1505-1507, 2022 | | 2022 |
| Intratumoral CD40 agonist sotigalimab with pembrolizumab induces broad innate and adaptive immune activation in local and distant tumors in metastatic melanoma. SE Bentebibel, D Johnson, R Amariae, D McGrail, S Lecagoonporn, ... CANCER RESEARCH 82 (12), 2022 | | 2022 |
| Abstract CT039: Intratumoral CD40 agonist sotigalimab with pembrolizumab induces broad innate and adaptive immune activation in local and distant tumors in metastatic melanoma SE Bentebibel, D Johnson, R Amariae, D McGrail, S Lecagoonporn, ... Cancer Research 82 (12_Supplement), CT039-CT039, 2022 | | 2022 |
| 808 Tertiary lymphoid structure gene signature detected in immune checkpoint inhibitor-associated renal immune related adverse event J Lin, A Tchakarov, N Abdel-Wahab, H Safa, SE Bentebibel, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), A845-A845, 2021 | | 2021 |
| Trends in PRO reporting in clinical trials leading to GU cancer drug approvals from 2007 to 2018. M Tamil, H Safa, A Semaan, J Chahoud Journal of Clinical Oncology 38 (6_suppl), 641-641, 2020 | | 2020 |
| Trends in PRO reporting in clinical trials leading to cancer immunotherapy drug approvals from 2011 to 2019. H Safa, M Tamil, A Diab, A Semaan, J Chahoud Journal of Clinical Oncology 38 (5_suppl), 105-105, 2020 | | 2020 |
